RxDoctor Payments Data

Alex Maese

Nurse Practitioner · Las Cruces, NMNPI 1952774523

Payments from drug & device makers

$511in general payments, 2019–2025

Across 14 payments — averaging $36.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$124
  • Sanofi-aventis U.S. LLC$103
  • Neurocrine Biosciences, Inc.$65
  • Axsome Therapeutics, Inc.$59
  • Alkermes, Inc.$57
  • Otsuka America Pharmaceutical, Inc.$30
  • plus $74 from 3 others

What the payments were for

  • Food & beverage$511100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$511 in reported general payments places this provider in the 80th percentile of 624 nurse practitioner providers in New Mexico.

See all nurse practitioner providers in New Mexico

Medicare billing

Part B allowed, 2024
$78,154
Medicare patients
160
Services billed
564

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin22$67,533
EliquisApixaban65$47,346
JanuviaSitagliptin Phosphate25$26,598
MyrbetriqMirabegron23$19,668
FarxigaDapagliflozin Propanediol29$18,086
Tresiba Flextouch U-100Insulin Degludec33$18,007
XareltoRivaroxaban13$12,198
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$11,074
EntrestoSacubitril/Valsartan11$9,384
JardianceEmpagliflozin13$9,269
SantylCollagenase Clostridium Hist.12$9,185
Combivent RespimatIpratropium/Albuterol Sulfate16$7,314
Atorvastatin Calcium431$7,199
VascepaIcosapent Ethyl20$5,420
TrintellixVortioxetine Hydrobromide11$5,236

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$25$5,23611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 624 nurse practitioner providers in New Mexico.

Other nurse practitioner in Las Cruces

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →